BMI View: The UAE will remain one of the most attractive pharmaceutical and healthcare markets in the
Middle East and Africa Region. A rising chronic disease burden will drive demand for high-value
medicines, particularly cancer drugs. The market is dominated by patented medicines, mainly imported
from Western suppliers due to their perceived superiority. However, this current model is unsustainable
over the long term and as such, the supply of generic cancer medicines in the UAE will increasingly be
satisfied by the domestic industry, limiting the country's escalating healthcare costs.
Headline Expenditure Projections
- Pharmaceuticals: AED10.77bn (USD2.93bn) in 2015 to AED11.62bn (USD3.17bn) in 2016; +7.9% in
local currency terms and +8.0% US dollar terms. Forecast in line with last quarter.
- Healthcare: AED56.32bn (USD15.33bn) in 2015 to AED59.18bn (USD16.13bn) in 2016; +5.1% in
local currency terms and +5.2% in US dollar terms. Forecast revised upwards from last quarter.